Manufacturers Life Insurance Company, The Aadi Bioscience, Inc. Transaction History

Manufacturers Life Insurance Company, The

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$4.84 - $7.13 $11,795 - $17,375	-2,437 Reduced 7.44%	30,330 $146,000
Q2 2023 Aug 11, 2023	SELL	$6.84 - $8.56 $39,412 - $49,322	-5,762 Reduced 14.95%	32,767 $224,000
Q4 2022 Aug 11, 2023	SELL	$11.99 - $14.5 $3,393 - $4,103	-283 Reduced 0.73%	38,529 $494,000
Q4 2022 Feb 13, 2023	SELL	$11.99 - $14.5 $3,393 - $4,103	-283 Reduced 0.73%	38,529 $494,000
Q3 2022 Aug 11, 2023	BUY	$12.03 - $14.22 $481 - $568	40 Added 0.1%	38,812 $548,000
Q3 2022 Nov 03, 2022	BUY	$12.03 - $14.22 $481 - $568	40 Added 0.1%	38,812 $535,000
Q2 2022 Aug 11, 2023	BUY	$11.57 - $17.92 $138,203 - $214,054	11,945 Added 44.53%	38,772 $477,000
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $138,203 - $214,054	11,945 Added 44.53%	38,772 $499,000
Q1 2022 Aug 11, 2023	SELL	$16.65 - $24.97 $194,838 - $292,198	-11,702 Reduced 30.37%	26,827 $455,000
Q1 2022 May 20, 2022	BUY	$16.65 - $24.97 $446,669 - $669,870	26,827 New	26,827 $463,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $46.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.